MONASH University Institute of Pharmaceutical Sciences (MIPS) has announced positive results from a first-in-human study of a new, inhaled form of a medicine that could significantly reduce postpartum haemorrhage (PPH)maternal deaths around the world.
Researchers at MIPS, in collaboration with GlaxoSmithKline in London, who sponsored the study, have been developing an inhalable, dry-powder form of oxytocin to replace the currently used temperature-sensitive injectable form.
CLICK HERE for a summary.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Mar 17
